EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Delivering the future of paediatric brain tumour therapy October 7, 2021 Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched... November 11, 2024 News digest – cancer blood test, gum disease and junk food... July 25, 2020 Load more HOT NEWS Survivors of Childhood Cancer are at Excess Risk of Late Mortality... Five Questions with…Debra. European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 Teacher Reads To Students One Day After Having Brain Surgery
